Filing Flows › Silence Therapeutics (SLN) › Q1 2026 › vs Q4 2025
Silence Therapeutics (SLN) Q1 2026 vs Q4 2025 (quarter over quarter)
Silence Therapeutics's revenue rose $388K (12×) from $34K in Q4 2025 to $422K in Q1 2026.
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $422K | $34K | $388K | 12× |
| Other income, net | $780K | $691K | $89K | +13% |
| Net loss | $15.0M | $11.8M | $3.2M | +27% |
| Costs & expenses | $16.2M | $12.5M | $3.7M | +29% |
| Operating costs | $16.2M | $12.5M | $3.7M | +29% |
| Cost of revenue | $11K | $12K | −$1K | -8% |
| Research & development | $9.1M | $8.7M | $373K | +4% |
| General & admin | $7.0M | $3.7M | $3.3M | +88% |
| Operating cash sources | $18.1M | $17.4M | $758K | +4% |
| Depreciation | $72K | $77K | −$5K | -6% |
| Share-based compensation | $2.4M | $0 | $2.4M | — |
| Cash used in operations | $15.6M | $17.3M | −$1.7M | -10% |
| Net loss absorbed | $15.0M | $11.8M | $3.2M | +27% |
| Working capital & other | $3.2M | $5.6M | −$2.4M | -43% |
Questions
How much did Silence Therapeutics's revenue grow quarter over quarter in Q1 2026?
Silence Therapeutics's revenue rose $388K (12×) from $34K in Q4 2025 to $422K in Q1 2026.